SCHEMBL3972107

SCHEMBL3972107

CCCCN(C)c1nc(-c2ccc(Br)cc2)nc2cc(OC)c(OC)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LATS1 O95835 1/20 0.50
LATS2 Q9NRM7 1/20 0.50
SLC2A1 P11166 1/20 0.46
WHR1 P49842 1/20 0.45
EHMT2 Q96KQ7 3/20 0.43
EHMT1 Q9H9B1 3/20 0.43
KDM1A O60341 2/20 0.42
RCOR1 Q9UKL0 1/20 0.42
EGFR P00533 2/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
MAPK1 P28482 1/20 0.38
GBA1 P04062 1/20 0.38
KDR P35968 1/20 0.38
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 2/20 0.38
STAT6 P42226 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ENPP1 P22413 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975863 0.91 KDM1A (0.49) LATS1LATS2SLC2A1WHR1EHMT2
SCHEMBL3978935 0.82 LATS1 (0.52) LATS1LATS2MAPTNPSR1MAPK1
SCHEMBL4238650 0.81 PDE5A (0.58) SLC2A1WHR1EHMT2EHMT1MAPT
SCHEMBL3972075 0.81 ADORA3 (0.52) LATS1LATS2SLC2A1MAPTLMNA
SCHEMBL3974654 0.77 ACP1 (0.54) LATS1LATS2SLC2A1WHR1EHMT2
SCHEMBL3980771 0.77 EHMT2 (0.51) EHMT2EHMT1EGFR
SCHEMBL7261412 0.76 KMT2A (0.46) WHR1EHMT2EHMT1KDM1ARCOR1
SCHEMBL3972104 0.75 SLC2A1 (0.47) SLC2A1WHR1KDM1AEGFRMAPT
SCHEMBL3976899 0.75 SPIN1 (0.49) SLC2A1WHR1EHMT2EHMT1NPSR1
SCHEMBL3973396 0.74 TLR9 (0.56) SLC2A1WHR1EHMT2KDM1ARCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 LATS1 4427/4885LATS2 4548/4885SLC2A1 1107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.